148 related articles for article (PubMed ID: 15926676)
1. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine.
Gupta P; Bansal AK
Pharm Dev Technol; 2005; 10(2):273-81. PubMed ID: 15926676
[TBL] [Abstract][Full Text] [Related]
2. Molecular interactions in celecoxib-PVP-meglumine amorphous system.
Gupta P; Bansal AK
J Pharm Pharmacol; 2005 Mar; 57(3):303-10. PubMed ID: 15807985
[TBL] [Abstract][Full Text] [Related]
3. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
4. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
Ghanavati R; Taheri A; Homayouni A
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614
[TBL] [Abstract][Full Text] [Related]
5. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
[TBL] [Abstract][Full Text] [Related]
6. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.
Gupta P; Bansal AK
PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422
[TBL] [Abstract][Full Text] [Related]
7. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
8. Impact of surfactants on the crystal growth of amorphous celecoxib.
Mosquera-Giraldo LI; Trasi NS; Taylor LS
Int J Pharm; 2014 Jan; 461(1-2):251-7. PubMed ID: 24333451
[TBL] [Abstract][Full Text] [Related]
9. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
[TBL] [Abstract][Full Text] [Related]
10. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility.
Gupta P; Bansal AK
Pharmazie; 2005 Nov; 60(11):830-6. PubMed ID: 16320944
[TBL] [Abstract][Full Text] [Related]
11. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
Gupta P; Kakumanu VK; Bansal AK
Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
13. Study on mechanism for amorphous drug stabilization using gelucire 50/13.
Shimpi SL; Mahadik KR; Paradkar AR
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253
[TBL] [Abstract][Full Text] [Related]
14. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
[TBL] [Abstract][Full Text] [Related]
15. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability.
Dhumal RS; Biradar SV; Aher S; Paradkar AR
J Pharm Pharmacol; 2009 Jun; 61(6):743-51. PubMed ID: 19505364
[TBL] [Abstract][Full Text] [Related]
16. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
17. Anomalous properties of spray dried solid dispersions.
Al-Obaidi H; Brocchini S; Buckton G
J Pharm Sci; 2009 Dec; 98(12):4724-37. PubMed ID: 19455622
[TBL] [Abstract][Full Text] [Related]
18. Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions.
Thybo P; Kristensen J; Hovgaard L
Pharm Dev Technol; 2007; 12(1):43-53. PubMed ID: 17484143
[TBL] [Abstract][Full Text] [Related]
19. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
Ha ES; Choo GH; Baek IH; Kim MS
Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
[TBL] [Abstract][Full Text] [Related]
20. An investigation into the effect of spray drying temperature and atomizing conditions on miscibility, physical stability, and performance of naproxen-PVP K 25 solid dispersions.
Paudel A; Loyson Y; Van den Mooter G
J Pharm Sci; 2013 Apr; 102(4):1249-67. PubMed ID: 23359268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
